Lesson plan

Synaffix

Synaffix is a Dutch biotechnology company headquartered in the Netherlands that has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs), primarily used for cancer treatment. ADCs utilize potent small molecule payloads, similar to those used in chemotherapy, but are designed to target only cancer cells, sparing normal, healthy tissues. The proprietary technology of Synaffix was developed to enable the treatment of a wide variety of cancer types and is designed to significantly enhance effectiveness while improving the safety and tolerability of these targeted cancer therapeutics. Benchmarking studies consistently demonstrate that, with a given antibody and ADC payload, ADCs produced using Synaffix technology display significantly enhanced effectiveness, tolerability, and safety compared to all three major clinical-stage ADC technologies. The most advanced ADC employing Synaffix technology was given to the first cancer patients in 2018. In October 2016, Synaffix made the first public disclosure of its commercial license agreement with ADC Therapeutics Sarl (ADCT). Under the terms of the agreement, ADCT may develop one or multiple products using Synaffix technology.…

Back to article

Article summary

Synaffix is a Dutch biotechnology company headquartered in the Netherlands that has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs), primarily used for cancer treatment. ADCs utilize potent small molecule payloads, similar to those used in chemotherapy, but are designed to target only cancer cells, sparing normal, healthy tissues. The proprietary technology of Synaffix was developed to enable the treatment of a wide variety of cancer types and is designed to significantly enhance effectiveness while improving the safety and tolerability of these targeted cancer therapeutics. Benchmarking studies consistently demonstrate that, with a given antibody and ADC payload, ADCs produced using Synaffix technology display significantly enhanced effectiveness, tolerability, and safety compared to all three major clinical-stage ADC technologies. The most advanced ADC employing Synaffix technology was given to the first cancer patients in 2018. In October 2016, Synaffix made the first public disclosure of its commercial license agreement with ADC Therapeutics Sarl (ADCT). Under the terms of the agreement, ADCT may develop one or multiple products using Synaffix technology.…

Key claims

  1. date of foundation: 2010 — source: Wikipedia, revision 1359540656, retrieved 2026-10-20 · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the date of foundation is "2010". What evidence would count against this claim?
  3. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  4. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia, “Synaffix”, revision 1359540656, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1359540656

Key claims and bibliography are generated from the same tracked claims and sources as the article page.